Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension
- PMID: 18360047
- DOI: 10.1291/hypres.31.271
Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension
Abstract
Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative stress in animal studies. We investigated candesartan's effect on the production of NO and oxidative stress as well as on carotid intima-media thickness (IMT) in hypertensive patients. One-hundred age-matched hypertensive patients were enrolled into an angiotensin II receptor blocker (ARB) group (n=50) or a non-ARB group (n=50). The ARB group was treated with candesartan 8 mg and, when needed, Ca channel blockers, angiotesin-converting enzyme (ACE) inhibitors, and/or beta-blockers. The non-ARB group was treated with drugs other than ARB. Carotid IMT was assessed by echocardiography before and 12 and 24 months after treatment. The urine levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an indicator of oxidative stress, and the serum levels of NOx, an indicator of NO, were measured. Blood pressure decreased to below 140/90 mmHg to the same extent in both groups. Carotid IMT decreased significantly in the ARB group, but not in the non-ARB group, at 12 and 24 months after treatment. The urine levels of 8-OHdG decreased significantly at 6 and 12 months after treatment in the ARB group but did not decrease in the non-ARB group. The serum levels of NOx increased significantly at 6 and 12 months after treatment in the ARB group but not in the non-ARB group. In conclusion, candesartan decreases carotid IMT by enhancing NO production and decreasing oxidative stress in patients with hypertension.
Similar articles
-
[Protective vascular effect of angiotensin receptor blocker (ARB)].Nihon Rinsho. 2002 Oct;60(10):2020-7. Nihon Rinsho. 2002. PMID: 12397701 Review. Japanese.
-
Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers.Am J Nephrol. 2006;26(5):462-8. doi: 10.1159/000096581. Epub 2006 Oct 24. Am J Nephrol. 2006. PMID: 17063001
-
Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.Am J Hypertens. 2008 Jan;21(1):72-7. doi: 10.1038/ajh.2007.5. Am J Hypertens. 2008. PMID: 18091747
-
Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.Am Heart J. 2008 Dec;156(6):1154.e1-8. doi: 10.1016/j.ahj.2008.09.006. Am Heart J. 2008. PMID: 19033012 Clinical Trial.
-
[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].Nihon Rinsho. 2003 Jul;61(7):1245-9. Nihon Rinsho. 2003. PMID: 12877092 Review. Japanese.
Cited by
-
Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes.Clin Exp Nephrol. 2015 Oct;19(5):909-17. doi: 10.1007/s10157-015-1088-0. Epub 2015 Feb 3. Clin Exp Nephrol. 2015. PMID: 25644676
-
Reactive oxygen species: key regulators in vascular health and diseases.Br J Pharmacol. 2018 Apr;175(8):1279-1292. doi: 10.1111/bph.13828. Epub 2017 Jul 11. Br J Pharmacol. 2018. PMID: 28430357 Free PMC article. Review.
-
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.Cardiovasc Diabetol. 2012 Oct 3;11:118. doi: 10.1186/1475-2840-11-118. Cardiovasc Diabetol. 2012. PMID: 23034088 Free PMC article. Clinical Trial.
-
Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study.Mediators Inflamm. 2020 May 11;2020:8143835. doi: 10.1155/2020/8143835. eCollection 2020. Mediators Inflamm. 2020. PMID: 32454794 Free PMC article. Clinical Trial.
-
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.Cardiovasc Diabetol. 2020 Jul 9;19(1):110. doi: 10.1186/s12933-020-01079-4. Cardiovasc Diabetol. 2020. PMID: 32646498 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous